Zolbetuximab
佐妥昔单抗CLDN18.2-directed monoclonal antibody newly added to the 2026 NRDL Negotiated List (#287) for first-line CLDN18.2+ HER2- gastric/GEJ adenocarcinoma.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字SJ20240050
- Initial Approval Date
- Dec 25, 2024
- Notice Published
- Dec 31, 2024
- MAH
- Astellas Pharma (安斯泰来制药)
- Approved Scope
- First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #287 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to first-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-based chemotherapy.
- 限联合含氟尿嘧啶类和铂类药物化疗用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字SJ20240050 | Powder for Injection (注射剂) 100mg/瓶 | Initial Approval First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. 联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。 | Approved: 2024-12-25 Published: 2024-12-31 | Astellas Pharma |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo.
Chinese original: 新增纳入2026版谈判药品第287项(乙类,支付标准*),限一线治疗CLDN18.2阳性、HER2阴性局部晚期或转移性胃/GEJ腺癌。
NHSA · PDF p.148Verified 2026-11-20 - (2024-12-25)NMPA Approval· Notice published: Dec 31, 2024
NMPA Initial Marketing Approval (国药准字SJ20240050 · 100mg/瓶)
First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Chinese original: 联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。
NMPA · NMPA Approval Announcement 2024-12-31Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20